Depo-Provera MDL 3140: the July count is up, and records matter now

Depo-Provera calls usually start with a pause.

"I know I got the shot. I just don't know how to prove it."

That is the problem many women are running into. The shot may have been at
an OB/GYN office, a county clinic, a college health center, or a primary
care practice that has changed names twice since then. The diagnosis is in
one set of records. The injection history is somewhere else.

For the Depo-Provera meningioma litigation, that paper trail matters.

The federal cases are grouped in MDL No. 3140, In re: Depo-Provera
(Depot Medroxyprogesterone Acetate) Products Liability Litigation, in the
Northern District of Florida before Judge M. Casey Rodgers. The Judicial
Panel on Multidistrict Litigation's July 1, 2026 report lists 5,830
pending actions and 5,916 total actions.

That is the court's number. Not a marketing estimate.

What the lawsuits are about

The lawsuits generally say Pfizer and related companies did not warn women
and doctors clearly enough about meningioma risk after repeated or
long-term use of medroxyprogesterone acetate injections.

Meningioma is often described as benign. Sometimes it is. But a tumor near
the brain or spinal cord can still mean surgery, radiation consults,
seizures, vision changes, headaches, repeated MRIs, and a long stretch of
not knowing what comes next. Families do not hear "benign" and feel fine.

The MDL does not mean the court has ruled that Pfizer is responsible. It
means many federal cases with similar allegations are being managed in one
court for discovery, expert issues, scheduling, and possible trial work.

Why the July number matters

A docket with more than 5,800 pending federal actions usually starts to run
on systems: fact sheets, medical record requests, proof of product use,
proof of diagnosis, deadlines, and review procedures.

That sounds dull. It is also where cases often live or die.

If you think you may have a claim, do not wait until every court deadline
is public and neatly explained. Start looking for records now. Old patient
portals close. Clinics merge. Pharmacies may not keep everything forever.
Insurance explanation-of-benefits forms sometimes survive when clinic
records are harder to get.

The label changed

The current FDA-approved Depo-Provera CI prescribing information now has a
meningioma warning. It says cases of meningiomas have been reported after
repeated administration of medroxyprogesterone acetate, primarily with
long-term use. It also tells clinicians to monitor for signs and symptoms
of meningioma and to discontinue Depo-Provera CI if a meningioma is
diagnosed.

That warning is not a substitute for medical advice. If you are using
Depo-Provera now, talk with your own clinician before stopping or changing
contraception.

Legally, though, the label is important. Many claims ask whether women who
used the shot before that warning was added should have been told more.

What the studies say

A 2024 BMJ study from France reported an association between prolonged
medroxyprogesterone acetate use and surgically treated intracranial
meningioma. The Pediatric Endocrine Society's March 2026 FDA-label summary
cited the study's adjusted odds ratio of 5.55, while also noting that the
absolute risk remains low.

ACOG gives patients a careful version of the risk. Its counseling guide
says the French study suggested a small increased risk, but the overall
risk of meningioma is still very low: about five out of 10,000 women using
medroxyprogesterone acetate compared with one out of 10,000 women not
using it. ACOG also notes limitations in the study and recommends shared
decision-making between patients and clinicians.

So the fair reading is not panic. It is caution, records, and a real
conversation with a doctor.

Records to save

If you used Depo-Provera and later received a meningioma diagnosis, look
for anything that can tie down both sides of the story:

• injection records from an OB/GYN, clinic, health department, college
  health office, or primary care practice;
• pharmacy records, if the shot was dispensed or billed through a pharmacy;
• insurance forms showing injection visits;
• MRI or CT reports;
• neurology, neurosurgery, radiation oncology, hospital, or pathology
  records;
• records showing surgery, monitoring, vision problems, seizures,
  headaches, or other symptoms;
• rough start and stop dates for the shots.

Do not throw away partial information. A clinic name and a year can help. A
city and an old insurance plan can help. A screenshot from a portal can
help.

Settlement talk is not the same as a case review

Public legal trackers have reported activity around settlement discussions,
Daubert timing, bellwether planning, and court scheduling. Those updates
can be important, but they do not answer the personal question: do your
records support a claim?

Be wary of anyone promising a specific payout. A reported framework, a
trial date, or a postponed hearing does not guarantee compensation. Case
value depends on proof, diagnosis, timing, state law, and whatever rules
the court or any claims process uses.

Who may want a review

A review may make sense if you used Depo-Provera or another
medroxyprogesterone acetate injection and later were diagnosed with a
meningioma. The best starting point is proof of injections plus medical
records confirming the tumor and treatment.

We help potential claimants sort out whether their records may fit the
Depo-Provera meningioma litigation and connect them with legal teams
reviewing these cases. No outcome is guaranteed. A lawyer has to review the
facts before saying whether a claim can be filed.

This article is attorney advertising and is for informational purposes
only. It is not medical advice and does not create an attorney-client
relationship.

Sources checked

• JPML, Pending MDL Dockets by Actions Pending, July 1, 2026.
• JPML, Pending MDL Dockets by MDL Number, July 1, 2026.
• FDA, Depo-Provera CI prescribing information, revised December 2025.
• Pediatric Endocrine Society, "Depo-Provera and Increased Risk of
  Meningioma: FDA-Label Update," March 30, 2026.
• ACOG, "Counseling Patients on Birth Control Injection and Meningioma."
• Lawsuit Information Center, Depo-Provera lawsuit update page, checked
  July 16, 2026.